Combination therapy for dyslipidemia
Author:
- 1 September 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 26 (5) , 420-423
Abstract
Residual cardiovascular risk remains in individuals treated with statins and combination therapies may reduce this risk further. Most previous trials of combination therapies have shown a favorable effect on lipid profiles without clinical superiority over statin monotherapy. Trial design has been hampered by short duration and comparison with a low dose statin. The Study of Heart and Renal Protection trial has recently reported findings and shows a benefit of ezetimibe/simvastatin over simvastatin alone. AIM-HIGH (Atherothrombosis Intervention in Metabolic syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes), a trial of statin/niacin, has been prematurely halted for futility. Finally, combining a statin with both niacin and ezetimibe shows significant enhancement of the therapeutic effect on lipid profiles. Current evidence continues to support initiation of a potent statin with titration to achieve targets. Combinations may be useful in individuals unable to reach desired lipid levels on maximal tolerated doses of statins.Keywords
This publication has 24 references indexed in Scilit:
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Effects of niacin on atherosclerosis and vascular functionCurrent Opinion in Cardiology, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Effects of Combination Lipid Therapy in Type 2 Diabetes MellitusNew England Journal of Medicine, 2010
- Extended-Release Niacin or Ezetimibe and Carotid Intima–Media ThicknessNew England Journal of Medicine, 2009
- Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for DyslipidemiaAnnals of Internal Medicine, 2009
- Effect of Statins Alone Versus Statins Plus Ezetimibe on Carotid Atherosclerosis in Type 2 DiabetesJACC, 2008
- Update on the use of fibrates: focus on bezafibrateVascular Health and Risk Management, 2008
- High-Density Lipoprotein as a Therapeutic TargetJAMA, 2007
- Effects of Nicotinic Acid Therapy on Plasma High Density Lipoprotein Subfraction Distribution and Composition and on Apolipoprotein A MetabolismJournal of Clinical Investigation, 1979